<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781179</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0447</org_study_id>
    <nct_id>NCT04781179</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of Mental Contrasting and Implementation Intention in the Management of Apathy in Schizophrenia</brief_title>
  <acronym>COMEIA</acronym>
  <official_title>Randomized, Controlled Study of the Effectiveness of Mental Contrasting and Implementation Intention in the Management of Apathy in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a mental pathology that concerns 1% of the French population, characterized&#xD;
      by heterogeneity of symptoms. One of them, apathy is defined as a multidimensional&#xD;
      psychopathological state manifested by a decrease in motivation. This deficit is most common&#xD;
      in schizophrenia and impacts the functional outcome of patients. To date, no treatment has&#xD;
      shown a significant effect on this symptom. In other pathologies with a motivational deficit,&#xD;
      the technique of Mental Contrasting and Implementation Intention (CM-II) showed interesting&#xD;
      effects in improving motivation, reducing the effort related to the action.&#xD;
&#xD;
      The investigators aim to propose the CM-II technique to individuals with schizophrenia to&#xD;
      improve apathy.&#xD;
&#xD;
      The investigators expected that the CM-II technique will allow an improvement of apathy which&#xD;
      will have beneficial effects on other psychological factors (e.g., depressive symptoms). In&#xD;
      addition, the implementation of the CM-II will provide help to global management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of at least one class at the Lille Apathy Rating Scale (LARS) at 3 months</measure>
    <time_frame>Change between Baseline and 3 months</time_frame>
    <description>LARS (Sockeel et al. 2006, translated and validated in French by Yazbek et al. 2014) is a questionnaire semi-structured based on a multidimensional approach to apathy. It is composed of 33 grouped items in nine dimensions: activities of daily living, interests, taking initiative, interest in novelty, voluntary efforts, the intensity of emotions, worry, social life, and self-critical capability. Each item can be rated at 1 (no) or -1 (yes), a score of 0 is possible. if the answer is not classifiable. The total score on this scale ranges from -36 to +36 and allows for different classes: non-apathetic (score -36 to -22); tendency to apathy (-21 to -17); moderate apathy (-16 to -10); and severe apathy (-9 to +36).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the improvement of at least one class at the Lille Apathy Rating Scale (LARS) at 1 month</measure>
    <time_frame>Change between Baseline and 1 month</time_frame>
    <description>LARS (Sockeel et al. 2006, translated and validated in French by Yazbek et al. 2014) is a questionnaire semi-structured based on a multidimensional approach to apathy. It is composed of 33 grouped items in nine dimensions: activities of daily living, interests, taking initiative, interest in novelty, voluntary efforts, the intensity of emotions, worry, social life, and self-critical capability. Each item can be rated at 1 (no) or -1 (yes), a score of 0 is possible. if the answer is not classifiable. The total score on this scale ranges from -36 to +36 and allows for different classes: non-apathetic (score -36 to -22); tendency to apathy (-21 to -17); moderate apathy (-16 to -10); and severe apathy (-9 to +36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the improvement of at least one class at the Lille Apathy Rating Scale (LARS) at 6 months</measure>
    <time_frame>Change between Baseline and 6 months</time_frame>
    <description>LARS (Sockeel et al. 2006, translated and validated in French by Yazbek et al. 2014) is a questionnaire semi-structured based on a multidimensional approach to apathy. It is composed of 33 grouped items in nine dimensions: activities of daily living, interests, taking initiative, interest in novelty, voluntary efforts, the intensity of emotions, worry, social life, and self-critical capability. Each item can be rated at 1 (no) or -1 (yes), a score of 0 is possible. if the answer is not classifiable. The total score on this scale ranges from -36 to +36 and allows for different classes: non-apathetic (score -36 to -22); tendency to apathy (-21 to -17); moderate apathy (-16 to -10); and severe apathy (-9 to +36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the score at the Calgary Depression Scale for Schizophrenia (CDSS) at 1 month</measure>
    <time_frame>Change between Baseline and 1 month</time_frame>
    <description>The Calgary Depression Scale for Schizophrenia (CDSS, Addington et al., 1993; validated in French; Bernard et al., 1998) is a nine-item structured interview assessing depression in schizophrenia that measures the severity of symptoms such as depressed mood, hopelessness, guilt, insomnia and suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the score at the Calgary Depression Scale for Schizophrenia (CDSS) at 3 months</measure>
    <time_frame>Change between Baseline and 3 months</time_frame>
    <description>The Calgary Depression Scale for Schizophrenia (CDSS, Addington et al., 1993; validated in French; Bernard et al., 1998) is a nine-item structured interview assessing depression in schizophrenia that measures the severity of symptoms such as depressed mood, hopelessness, guilt, insomnia and suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the score at the Calgary Depression Scale for Schizophrenia (CDSS) at 6 months</measure>
    <time_frame>Change between Baseline and 6 months</time_frame>
    <description>The Calgary Depression Scale for Schizophrenia (CDSS, Addington et al., 1993; validated in French; Bernard et al., 1998) is a nine-item structured interview assessing depression in schizophrenia that measures the severity of symptoms such as depressed mood, hopelessness, guilt, insomnia and suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the &quot; negative symptoms &quot; sub-score of the Positive And Negative Syndrome Scale (PANSS, Kay et al., 1987) at 1 month</measure>
    <time_frame>Change between Baseline and 1 month</time_frame>
    <description>The Positive And Negative Syndrome Scale is a scale hetero-evaluation of positive and negative symptomatology and general psychopathology in schizophrenia, consisting of 30 items, sides 1 to 7. The higher the score, the more severe the symptomatology. This scale provides scores on three syndromic dimensions: positive (7 items), negative (7 items) and positive (7 items), and general psychopathology (16 items) from a categorical and dimensional perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the &quot; negative symptoms &quot; sub-score of the Positive And Negative Syndrome Scale (PANSS, Kay et al., 1987) at 3 months</measure>
    <time_frame>Change between Baseline and 3 months</time_frame>
    <description>The Positive And Negative Syndrome Scale is a scale hetero-evaluation of positive and negative symptomatology and general psychopathology in schizophrenia, consisting of 30 items, sides 1 to 7. The higher the score, the more severe the symptomatology. This scale provides scores on three syndromic dimensions: positive (7 items), negative (7 items) and positive (7 items), and general psychopathology (16 items) from a categorical and dimensional perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the &quot; negative symptoms &quot; sub-score of the Positive And Negative Syndrome Scale (PANSS, Kay et al., 1987) at 6 months</measure>
    <time_frame>Change between Baseline and 6 months</time_frame>
    <description>The Positive And Negative Syndrome Scale is a scale hetero-evaluation of positive and negative symptomatology and general psychopathology in schizophrenia, consisting of 30 items, sides 1 to 7. The higher the score, the more severe the symptomatology. This scale provides scores on three syndromic dimensions: positive (7 items), negative (7 items) and positive (7 items), and general psychopathology (16 items) from a categorical and dimensional perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increased percentage of personal goal attainment at 1 month</measure>
    <time_frame>Change between Baseline and 1 month</time_frame>
    <description>Participants will be asked to list the goals they wish to achieve in 6 months or less, and the percentage of goals achieved will be assessed by the question &quot;Were you able to achieve your goals? &quot;to determine whether or not each personal goal was achieved. The expected response is yes vs. no for each personal goal. This methodology corresponds to the one classically used in CM-II studies (Fritzsche et al., 2016).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increased percentage of personal goal attainment at 3 months</measure>
    <time_frame>Change between Baseline and 3 months</time_frame>
    <description>Participants will be asked to list the goals they wish to achieve in 6 months or less, and the percentage of goals achieved will be assessed by the question &quot;Were you able to achieve your goals? &quot;to determine whether or not each personal goal was achieved. The expected response is yes vs. no for each personal goal. This methodology corresponds to the one classically used in CM-II studies (Fritzsche et al., 2016).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increased percentage of personal goal attainment at 6 months</measure>
    <time_frame>Change between Baseline and 6 months</time_frame>
    <description>Participants will be asked to list the goals they wish to achieve in 6 months or less, and the percentage of goals achieved will be assessed by the question &quot;Were you able to achieve your goals? &quot;to determine whether or not each personal goal was achieved. The expected response is yes vs. no for each personal goal. This methodology corresponds to the one classically used in CM-II studies (Fritzsche et al., 2016).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased perception of effort associated with achieving goals at 1 month</measure>
    <time_frame>Change between Baseline and 1 month</time_frame>
    <description>Participants will be asked to report on their perception of the effort associated with goal attainment as assessed by the question &quot;Did achieving personal goals require you to make an effort? &quot;. Responses will be on a 10-points Likert scale ranging from 1 (&quot;no effort at all&quot;) to 10 (&quot;a lot of effort&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased perception of effort associated with achieving goals at 3 months</measure>
    <time_frame>Change between Baseline and 3 months</time_frame>
    <description>Participants will be asked to report on their perception of the effort associated with goal attainment as assessed by the question &quot;Did achieving personal goals require you to make an effort? &quot;. Responses will be on a 10-points Likert scale ranging from 1 (&quot;no effort at all&quot;) to 10 (&quot;a lot of effort&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased perception of effort associated with achieving goals at 6 months</measure>
    <time_frame>Change between Baseline and 6 months</time_frame>
    <description>Participants will be asked to report on their perception of the effort associated with goal attainment as assessed by the question &quot;Did achieving personal goals require you to make an effort? &quot;. Responses will be on a 10-points Likert scale ranging from 1 (&quot;no effort at all&quot;) to 10 (&quot;a lot of effort&quot;).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Apathy</condition>
  <arm_group>
    <arm_group_label>CM-II Technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychoeducation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CM-II</intervention_name>
    <description>It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique</description>
    <arm_group_label>CM-II Technique</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychoeducation</intervention_name>
    <description>It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation</description>
    <arm_group_label>Psychoeducation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 and &lt; 60 years old&#xD;
&#xD;
          -  Diagnosis of schizophrenia according to DSM 5 criteria.&#xD;
&#xD;
          -  Score greater than or equal to -18 on the Lille Apathy Rating Scale&#xD;
&#xD;
          -  Ability to understand and speak French.&#xD;
&#xD;
          -  Obligation to belong to or be a beneficiary of a social security scheme.&#xD;
&#xD;
          -  Signature of the consent. If the participant has a representative, signature by the&#xD;
             representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head injuries or neurological pathologies.&#xD;
&#xD;
          -  Current treatment with sismotherapy or repetitive Transcranial Magnetic Stimulation&#xD;
             (rTMS).&#xD;
&#xD;
          -  Treatment targeted at and/or influencing negative symptoms (CBT, cognitive&#xD;
             remediation), or therapeutic trial.&#xD;
&#xD;
          -  Participant under safeguard of justice.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amandine Decombe</last_name>
    <phone>+33467335435</phone>
    <email>a-decombe@chu-montpellier.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>implementation intention</keyword>
  <keyword>mental contrasting</keyword>
  <keyword>apathy</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>motivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

